About Polyneuron pharmaceuticals ag
Polyneuron Pharmaceuticals AG: Precision Treatment of Immune Disorders
Polyneuron Pharmaceuticals AG is a Swiss-based biotech company that specializes in the development of precision treatments for immune disorders. The company was founded in 2014 by Dr. Ruben Herrendorff and Dr. Pascal Hänggi, who are both experts in the field of neuroimmunology.
Polyneuron's mission is to develop innovative therapies that target specific components of the immune system, with the goal of providing safer and more effective treatments for patients suffering from autoimmune diseases and other immune-related disorders.
The company's proprietary technology platform, called Anticalin®, enables the design and production of highly specific protein therapeutics that can selectively bind to disease-causing molecules without affecting healthy tissues or cells. This approach allows for precise targeting of disease pathways while minimizing side effects.
Polyneuron has several drug candidates in its pipeline, including PN-1007 for anti-MAG neuropathy, PN-1011 for Guillain-Barré syndrome (GBS), and PN-1129 for multiple sclerosis (MS). These conditions are all characterized by abnormal immune responses that result in damage to nerve cells or other tissues.
Anti-MAG neuropathy is a rare neurological disorder caused by antibodies against myelin-associated glycoprotein (MAG), which leads to progressive weakness and sensory loss. GBS is an acute inflammatory disorder that affects peripheral nerves, causing muscle weakness and paralysis. MS is a chronic autoimmune disease that attacks the central nervous system, leading to various symptoms such as vision loss, muscle weakness, and cognitive impairment.
Polyneuron's drug candidates have shown promising results in preclinical studies and early-stage clinical trials. For example, PN-1007 demonstrated significant improvement in motor function and sensory perception in animal models of anti-MAG neuropathy. PN-1011 showed rapid recovery from GBS symptoms in a Phase 1b trial involving human patients. PN-1129 exhibited strong anti-inflammatory and neuroprotective effects in a mouse model of MS.
Polyneuron's innovative approach to precision medicine has attracted significant attention from investors and partners. The company has raised over CHF 40 million in funding from leading venture capital firms, such as Sofinnova Partners, Polaris Partners, and Pureos Bioventures. Polyneuron has also established collaborations with academic institutions and pharmaceutical companies, such as Roche and Sanofi.
In addition to its drug development programs, Polyneuron is actively pursuing research projects to expand its technology platform and explore new therapeutic areas. The company's scientific team includes experts in immunology, protein engineering, pharmacology, and clinical development.
Polyneuron is committed to advancing the field of precision medicine for immune disorders by leveraging its unique capabilities in protein engineering and disease biology. The company's vision is to transform the lives of patients who suffer from debilitating conditions that currently have limited treatment options.
In conclusion, Polyneuron Pharmaceuticals AG is a cutting-edge biotech company that is revolutionizing the field of precision medicine for immune disorders. With its proprietary Anticalin® technology platform and innovative drug candidates targeting specific components of the immune system, Polyneuron has the potential to provide safer and more effective treatments for patients suffering from autoimmune diseases and other immune-related disorders.